Tattersfield A E, Cragg D J
Br J Clin Pharmacol. 1983 Dec;16(6):587-90. doi: 10.1111/j.1365-2125.1983.tb02226.x.
To determine whether the beta 2-selectivity of ICI 118551 extended to human airways, we measured bronchial beta-adrenoceptor blockade and the reduction in exercise heart rate in six normal subjects on different occasions after ingestion of ICI 118551 20 or 50 mg, propranolol 40 mg or placebo in random order. Bronchial beta-adrenoceptor blockade after each active drug was measured as the displacement of the airway dose-response curve to salbutamol and expressed as a dose ratio. Exercise heart rate was measured during the fifth minute of steady state exercise at 70% of the subject's maximum work load. The mean dose ratios for the salbutamol airway dose-response curves following ICI 118551 20 and 50 mg and propranolol 40 mg were 11, 55 and 48 respectively. The mean reductions in exercise heart rate for the three drugs were 0.6, 6.6 and 16.6% respectively. These results confirm that the beta 2-selectivity of ICI 118551 includes airway beta 2-adrenoceptors in man.
为了确定ICI 118551的β2选择性是否扩展至人类气道,我们对6名正常受试者在不同时间随机服用20或50毫克ICI 118551、40毫克普萘洛尔或安慰剂后,测量了支气管β肾上腺素能受体阻滞情况以及运动心率的降低情况。每种活性药物后的支气管β肾上腺素能受体阻滞通过气道对沙丁胺醇剂量反应曲线的位移来测量,并表示为剂量比。运动心率在受试者最大工作负荷的70%的稳态运动的第五分钟期间测量。服用20毫克和50毫克ICI 118551以及40毫克普萘洛尔后,沙丁胺醇气道剂量反应曲线的平均剂量比分别为11、55和48。这三种药物运动心率的平均降低分别为0.6%、6.6%和16.6%。这些结果证实,ICI 118551的β2选择性在人体中包括气道β2肾上腺素能受体。